Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. Journal for Immunotherapy of Cancer 6, 38 (2018). https://t.co/CFOp2kYCdN
Interesting data. Since we know that NY-ESO-1-specific CD8+ T cells up-regulate PD-1 expression, wonder if this should be combined with checkpoint inhibitors? Particularly in light of Checkmate 238 results. @sitcancer #Melanoma #melsm #immunoOncology https
RT @sitcancer: #JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis htt…
RT @sitcancer: #JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis htt…
#JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis https://t.co/lE4uCJU3Im https://t.co/GojkmH1qdb
RT @sitcancer: #JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis htt…
RT @sitcancer: #JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis htt…
RT @sitcancer: #JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis htt…
#JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis https://t.co/mVx0C7EILv https://t.co/F3B6DbhKtj
#JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis https://t.co/mVx0C7EILv https://t.co/nSSxvhzN5T
RT @Immunotx_papers: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. https://t.co/…
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. https://t.co/M1SvoxEQ2W
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. https://t.co/YpAM0JJFoF
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. https://t.co/k8OLujGhO5
New #JITC Research: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected #melanoma: a retrospective cohort analysis https://t.co/mVx0C7EILv https://t.co/sDJr6cOdo0